

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p>		<b>Complete if Known</b>	
		Application Number	10/584,207
		Filing Date	June 23, 2006
		First Named Inventor	Colgan et al.
		Group Art Unit	1646
		Examiner Name	Unassigned
Sheet	1	of	3
		Attorney Docket Number	MTS5USA

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AA	ATHANASAS-PLATSIS "Passive immunization of pregnant mice against early pregnancy factor causes loss of embryonic viability", J Reprod Fertil, 87(2):495-502 (November 1989)	
	AB	ATHANASAS-PLATSIS "Antibodies to early pregnancy factor retard embryonic development in mice in vivo", J Reprod Fertil, 92(2):443-451 (July 1991)	
	AC	BARNETTE "Glutathione S-transferase in human endometrium: quantitation and interindividual variability in isoform content", Gynecol Obstet Invest, 47(2):114-119 (February 1999)	
	AD	BRYANT-GREENWOOD "High-Throughput Proteomic Analysis of Microdissected Cytological Specimens Yields Distinct Expression Profiles of Follicular vs Papillary Thyroid Carcinomas", Mod Pathol, 13:30A (2000)	
	AE	BUCKLEY "Normal endometrium and non-proliferative conditions of the endometrium", Fox H, Wells M. Eds. Churchill-Livingstone, 5 <sup>th</sup> Edition, pp. 391-442 (2003)	
	AF	CANCER FACTS AND FIGURES, American Cancer Society, pp. 1-52 (2003)	
	AG	GRADY "Endometrial Cancer", Cancer by Tissue of Origin, Cancer epidemiology and prevention, 2 <sup>nd</sup> Edition, pp. 1058-1089 (1996)	
	AH	GUO "Identification and Validation of Biomarkers for Endometrial Carcinoma after Discovery with ProteinChip Technology and SELDI MS", Proceedings of the 52nd ASMS Conference on Mass Spectrometry and Allied Topics, Nashville, Tennessee, (May 23-27, 2004)	
	AI	HARDT "Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening", Anticancer Res, 23(2A):855-857 (March-April 2003)	
	AJ	JOSEPH "Creatine kinase activity and isoenzymes in lung, colon and liver carcinomas" Br J Cancer, 76(5):600-605 (1997)	
	AK	KATO "The immunohistochemical expression of stress-response protein (srp) 60 in human brain tumours: relationship of srp 60 to the other five srps, proliferating cell nuclear antigen and p53 protein", Histol Histopathol, 16(3):809-20 (July 2001)	
	AL	KIM "Usefulness of plasma tumor M2-pyruvate kinase in the diagnosis of gastrointestinal cancer", Korean J Gastroenterol, 42(5):387-393 (November 2003)	

Examiner Signature	/Christina Borgeest/ (03/04/2010)	Date Considered	
--------------------	-----------------------------------	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CB/

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p><i>(Use as many sheets as necessary)</i></p>		<b>Complete if Known</b>	
		Application Number	10/584,207
		Filing Date	June 23, 2006
		First Named Inventor	Colgan et al.
		Group Art Unit	1646
		Examiner Name	Unassigned
Sheet	2	of	3
		Attorney Docket Number	MTS5USA

<b>NONPATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T <sup>2</sup>
	AM	KRISTINSSON "Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs. hemoccult II", Digestion, 64(2):104-110 (2001)		
	AN	MARSHALL "Enzymes of glucose metabolism in carcinoma of the cervix and endometrium of the human uterus", Br J Cancer, 37(6):990-1001 (June 1978)		
	AO	MARSHALL "Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction", J Proteome Res, 2(4):361-372 (July-August 2003)		
	AP	MARSHALL "Human serum proteins preseparated by electrophoresis or chromatography followed by tandem mass spectrometry", J Proteome Res, 3(3):364-82 (May-June 2004)		
	AQ	MEIER "Identification of cyclophilin A from human decidua and placental tissue in the first trimester of pregnancy", Hum Reprod, 10(5):1305-1310 (May 1995)		
	AR	MUNARON "Blocking Ca <sup>2+</sup> entry: a way to control cell proliferation", Curr Med Chem, 11(12):1533-1543 Review (June 2004)		
	AS	MUNCHBACH "Quantitation and facilitated de novo sequencing of proteins by isotopic N-terminal labeling of peptides with a fragmentation-directing moiety", Anal Chem, 72(17):4047-4057 (September 1, 2000)		
	AT	NOONAN "Early pregnancy factor is immunosuppressive", Nature, 278(5705):649-51 (April 12, 1979)		
	AU	OMENN "The HUPO Plasma Proteome Project Pilot Phase: Reference Specimens, Technology Platform Comparisons, and Standardized Data Submissions and Analyses" HUPO 2nd Annual & IUBMB XIX World Congress, Montreal, Quebec, (October 8-11, 2003)		
	AV	QUINN "Active immunization with EPF suppresses the formation of immune ascites in BALB/c mice", Immunol Cell Biol, 69(Pt 1):1-6 (February 1991)		
	AW	RICHARDSON "Biochemical markers of contraction in human myometrial smooth muscle cells in culture", In Vitro Cell Dev Biol, 23(1):21-28 (January 1987)		
	AX	ROSSEL "Nonspecific increased serum levels of secretory component in lung tumors: relationship to the gene expression of the transmembrane receptor form", Am J Respir Cell Mol Biol, 9(3):341-346 (September 1993)		

Examiner Signature	/Christina Borgeest/ (03/04/2010)	Date Considered	
--------------------	-----------------------------------	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CB/

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(Use as many sheets as necessary)</p>				<b>Complete if Known</b>	
				Application Number	10/584,207
				Filing Date	June 23, 2006
				First Named Inventor	Colgan et al.
				Group Art Unit	1646
				Examiner Name	Unassigned
Sheet	3	of	3	Attorney Docket Number	MTS5USA

**NONPATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AY	ROTH "Complex pattern of the myelo-monocytic differentiation antigens MRP8 and MRP14 during chronic airway inflammation", Immunobiology, 186(3-4):304-314 (November 1992)	
	AZ	TABIBZADEH "Heat shock proteins in human endometrium throughout the menstrual cycle", Hum Reprod., 11(3):633-640 (March 1996)	
	AAA	UCHIDA "Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid", J Proteome Res, 1(6):495-499 (November-December 2002)	
	AAB	VON EGGERLING "Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research", Biotechniques, 29(5):1066-1070 (November 2000)	
	AAC	WAGNER "A test before its time? FDA stalls distribution process of proteomic test", J Natl Cancer Inst, 96(7):500-501 (April 7, 2004)	
	AAD	XIAOGUANG "A Study of Early Pregnancy Factor Activity in the Sera of Women with Trophoblastic Tumor", Am J of Reproductive Immunology, 41:204-208 (1999)	
	AAE	YANG "Protein expression profiling of endometrial malignancies reveals a new tumor marker: chaperonin 10", J Proteome Res, 3(3):636-643 (May-June 2004)	
	AAF	YAO "Proteolytic <sup>18</sup> O labeling for comparative proteomics: model studies with two serotypes of adenovirus", Anal Chem, 73(13):2836-2842 (July 1, 2001)	
	AAG	ZHANG "A panel of three potential biomarkers discovered from serum proteomic profiling improves sensitivity of CA125 in the detection of early stage ovarian cancer - a multi-institutional study", Proceeding of the American Association for Cancer Research, 44(2):1145 (July 2003)	
	AAH	National Cancer Institute of Canada: Canadian Cancer Statistics, Toronto, 1-105 (April 2003)	

Examiner Signature	/Christina Borgeest/ (03/04/2010)	Date Considered	
--------------------	-----------------------------------	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.